http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
윤준로 ( Jun Rho Yoon ),정은용 ( Eun Yong Jung ),김미정 ( Mi Jung Kim ) 대한마취과학회 2009 Korean Journal of Anesthesiology Vol.56 No.1
Background: Advances in the field of interventional and diagnostic radiology have resulted in anesthesiologists becoming involved in angiographic suites. In the present study, we evaluated the characteristics of patients and the anesthetic management in an angiographic suite, to determine what factors influenced the patient outcome. Methods: Data pertaining to patients that were anesthetized at an angiographic suite in a university hospital between 1 January 2007 and 31 December 2007 were evaluated retrospectively. Specifically, we evaluated the patient characteristics and the types of anesthesia administered, to determine which factors were related to patient outcome. Results: Sixty-four percent of the patients enrolled in this study were women. Cases involving coiling for unruptured and ruptured aneurysm, embolization for intracranial arteriovenous malformation and fistula, pediatric diagnostic angiography, embolization for extracranial arteriovenous malformation, and implantable cardioverter-defibrillator (ICD) implantation all required the involvement of anesthesiologists. Major postoperatve complications included pneumonia, atelectasis, and hydrocephalus. In addition, GCS, net fluid balance, and anesthesia time had influence on patient outcome. Conclusions: We evaluated the characteristics of patient groups, procedures, and postoperative complications in an angiographic suite. The results of our analysis revealed that a through understanding of nervous and vascular pathology, as well as knowledge of current interventional radiology, neuroanesthesia and vascular anesthesia techniques is essential for development of safe and effective care. (Korean J Anesthesiol 2009;56:36~46)
사염화탄소와 에탄올로 유발된 간손상에 대한 GODEX<SUP>Ⓡ</SUP>의 치료효과 및 투여 중단에 따른 효소 역전 현상의 비교 평가
신지순(Ji Soon Sin),정은용(Eun Yong Jung),채희열(Hee-Youl Chai),권운(Woon Kwon),최은경(Ehn Kyoung Choi),조영민(Young Min Cho),황석연(Seok-Yeon Hwang),이민호(Min Ho Lee),김윤배(Yun-Bae Kim),강종구(Jong-Koo Kang) 한국실험동물학회 2003 Laboratory Animal Research Vol.19 No.4
새로운 간질환치료제(고덱스 : 헤파디프에스)의 랫드에 대한 4주반복투여 경구독성시험
강종구(Jong-Kii Kang),정은용(Eun-Yong Jung),박선희(Sun-Hee Park),김선희(Sun-Hee Kim),이수해(Su-Hae Lee),장호송(Hu-Song Zhang),황재식(Zai-Zhi Huang),남상윤(Sang-Yoon Nam) 한국독성학회 2001 Toxicological Research Vol.17 No.2
This study was designed to evaluate a repeated oral dose toxicity of a new hepatotherapeutic agent GODEX in Sprague-Dawley rats. Male and female rats were orally administered with dosages of 500, 100, 20, and a mg/kg/day of GODEX daily for 4 weeks, respectively. There were no dose-related changes in clinical signs, body weight changes, food and water consumption, opthalmoscopy, organ weights, urine analysis, biochemical examination, and hematological findings of all animals treated with GODEX. Gross and histopathological findings revealed no evidence of specific toxicity related to GODEX. These indicate that GODEX may have no side effects and its oral maximum tolerated dose value may be over 500 mg/kg in rats.
YHB216 의 비글개에서 정맥내 단회 및 4 주 반복투여독성시험
장호송(Hu Song Zhang),정은용(Eun Yong Jung),신지순(Ji Soon Sin),안경규(Kyoung Kyu Ahn),최연식(Yeon Shik Choi),강종구(Jong Koo Kang),노용우(Yong Woo Roh),지형진(Hyeong Jin Ji),강민정(Min Joung Kang),이종욱(Jong Wook Lee) 한국응용약물학회 2002 Biomolecules & Therapeutics(구 응용약물학회지) Vol.10 No.1
N/A Recently, recombinant human erythropoietin (rHu-EPO) has been used to treat various types of anemia. YHB216 is a new rHu-EPO developed by Yuhan Research Institute. In this study, we investigated the single dose and 4-week repeated dose toxicity of YHB216 in Beagle dogs. In the single dose toxicity study, YHB216 was administered intravenously at single dose levels of 0 and 25,000 IU/㎏ to dogs (2 dogs/sex/ group). There were no treatment-related changes in survivals, clinical signs, body weight gain, hematological values, blood chemical values, and necropsy finding during experimental period. In the repeated dose toxicity study, YHB216 was administered intravenously to dogs for 4 weeks at the dose levels of 0, 100, 500, and 2,500 IU/㎏ (3 dogs/sex/group). There were no toxicologically significant changes in clinical signs, body weights, food and water consumptions, ophthalmoscopy, urinalysis and blood chemistry. There were increased values of red blood cell, hemoglobin, and hematocrit at all treated groups. Spleen revealed increased weight and extramedullary hematopoiesis at 500 IU/㎏ or more. These changes are all considered to be pharmacology-related effects and were recovered after 4-week recovery period. From these results, it is concluded that LD_50 value was above 25,000 IU/㎏ in the single dose toxicity study of YHB216 in dogs and the no observed adverse effect level (NOAEL) was 100 IU/㎏/day in the repeated dose toxicity study of YHB216 in dogs.
새로운 간질환치료제 ( 고덱스 헤파디프에스 ) 의 랫드에 대한 단회투여 경구독성시험
강종구(Jong Koo Kang),정은용(Eun Yong Jung),남상윤(Sang Yoon Nam) 한국응용약물학회 2001 Biomolecules & Therapeutics(구 응용약물학회지) Vol.9 No.2
This study was performed to evaluate an single dose oral toxicity of a new hepatotherapeutic agent GODEX (HEPADIF-S) in Sprague-Dawley rats. Male and female rats were administered dosages of 5, 2.5, 1.25, 0.625, 0.3125, and 0 g/kg B.W. of GODEX, respectively. After single oral administration of GODEX to rats, we observed them daily for 2 weeks. GODEX did not induce any toxic signs in the mortalities, clinical signs, body weight changes, and gross necropsy findings of rats. Based on these results, it is concluded that GODEX may have no side effect and its LD_(50) value may be over 5 g/kg B.W. in rats.
임신토끼에 있어서 새로운 Recombinant Human Granulocyte Colony - Stimulating Factor ( YHB6211 ) 의 배 , 태자 발생독성평가
황재식(Zai Zhi Huang),이수해(Su Hae Lee),신지순(Ji Soon Sin),신장우(Jang Woo Sin),최연식(Yeon Shik Choi),김대중(Dae Joong Kim),장호송(Hu Song Zhang),정은용(Eun Yong Jung),서동석(Dong Suk Seo),안경규(Kyoung Kyu Ahn),남상윤(Sang Yoon N 한국응용약물학회 2001 Biomolecules & Therapeutics(구 응용약물학회지) Vol.9 No.4
N/A YHB6211, a newly developed recombinant human granulocyte colonystimulating factor, was administered at dose levels of 0, 3, 15, and 75 ㎍/㎏/day intravenously to the pregnant New Zealand White rabbits (20 rabbits per group) during the organogenetic period, days 6 to 18 of gestation. All dams were subjected to Caesarian section on day 28 of gestation and their fetuses were examined for external, visceral, and skeletal abnormalities. No abnormalities in clinical signs, body weight changes, gross findings, mortality, and external appearance were found in all dams and fetuses exposed to 0, 3, and 15 ㎍/㎏/day of YHB6211. However, in the group treated with 75 ㎍/㎏/day of YHB6211, maternal body and uterine weights, fetal body weights and length, and the number of live fetuses were significantly decreased and further fetal mortality was remarkably increased. It is suggested that YHB6211 may have no side effect up to the dose level of 15 ㎍/㎏/day, and there would be no teratogenicity for fetuses of rabbits up to 75 ㎍/㎏/day even if it may have some toxic effects over 75 ㎍/㎏/day for dams and fetuses of rabbits.